Hemostemix to Present Its Clinical Data of the Treatment of Severe Angina
Calgary, Alberta--(Newsfile Corp. - September 16, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, announces that Croom Lawren
Biotechnology, Pharmaceuticals, Health
2025-09-16 2:52 PM EDT | Hemostemix Inc.
Defence Therapeutics Appoints Dr. Amie Phinney as Director
Montreal, Quebec--(Newsfile Corp. - September 16, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce the appointment of Dr. Amie Phinney, PhD, MBA to its Board of Directors, effective immediately. Dr. Phinney recently joined Defence as a Strategy and Business Advisor, working closely with leadership to refine the Co
Biotechnology, Pharmaceuticals, Health
2025-09-16 3:15 AM EDT | Defence Therapeutics Inc.
Defence Therapeutics Completes Fully Subscribed Debenture Units Financing of $2,000,000
Montreal, Quebec--(Newsfile Corp. - September 15, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce the closing of its previously announced non-brokered private placement of debenture units (the "Units") at a price of $1,000 per Unit for aggregate gross proceeds of $2,000,000 (the "Offering"). Each Unit consisted of (i) on
Biotechnology, Pharmaceuticals, Health
2025-09-15 4:30 PM EDT | Defence Therapeutics Inc.
OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit
New York, New York--(Newsfile Corp. - September 12, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapi
2025-09-12 7:40 AM EDT | OS Therapies
BYT Announces Corporate Updates
Vancouver, British Columbia--(Newsfile Corp. - September 11, 2025) - BYT Holdings Ltd. (CSE: BYT) ("BYT" or the "Company") announces that it has entered into an agreement dated effective September 9, 2025 and sold all of the outstanding shares of its wholly-owned Singapore subsidiary, BYT Engineering PTE Ltd. ("BYT Engineering"), to an arm's length third party for an aggregate purchase price of SGD$10,000. The Company will continue to carry on the business activities of B
Technology, Biotechnology, Construction / Building, Machinery
2025-09-11 5:15 PM EDT | BYT Holdings Ltd.
Nextleaf Provides Strategic Update: Canada's First 200-Pack Cannabis Softgels, and Opening of Distribution Facility
Vancouver, British Columbia--(Newsfile Corp. - September 11, 2025) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), an innovation-driven life science company and licensed cannabis processor announces the launch of Canada's first 200-pack cannabis softgels under its house brand Glacial Gold™, and the opening of a new distribution facility. Together, these developments strengthen Nextleaf's position in existing markets and enh
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2025-09-11 9:00 AM EDT | Nextleaf Solutions Ltd.
Hemostemix Announces TSXV Approval of Debt Settlement at $0.20 per Share
Calgary, Alberta--(Newsfile Corp. - September 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, a
Biotechnology, Pharmaceuticals, Health
2025-09-10 4:37 PM EDT | Hemostemix Inc.
Izotropic Gains Visibility as AI Market Broadens Beyond Tech
British Columbia and Sacramento, California--(Newsfile Corp. - September 10, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces its sponsored placement in an editorial published on
2025-09-10 1:24 PM EDT | Izotropic Corporation
Envoy Medical Issues Letter to Shareholders and Provides Update on Recent Accomplishments
White Bear Lake, Minnesota--(Newsfile Corp. - September 10, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted technologies, today issued a letter to shareholders commenting on recent accomplishments and other operational updates from Chief Executive Officer, Brent Lucas. Dear Shareholders: The third quarter of 2025 has been one of tremendous progress and momentum for Envoy Medical. As "Amer
Biotechnology, Healthcare and Hospitals
2025-09-10 8:00 AM EDT | Envoy Medical, Inc.
MustGrow Secures $2 Million Line of Credit with CIBC; Guaranteed by EDC
Saskatoon, Saskatchewan--(Newsfile Corp. - September 10, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") is pleased to announce it has secured a $2.0 million line of credit with Canadian Imperial Bank of Commerce, guaranteed by Canada's Export Development Canada ("EDC") (the "LOC"). Access to funds will allow MustGrow to produce its organic mustard-derived biofertility product TerraSanteTM
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2025-09-10 7:00 AM EDT | MustGrow Biologics Corp.
BioHarvest Sciences Announces Breakthrough in Botanical Synthesis Capabilities with Plant-Based Exosome Production at Scale
Rehovot, Israel--(Newsfile Corp. - September 10, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it has successfully produced, at scale, plant-based exosomes in its bioreactor media, marking a significant advancement in the Company's proprietary Botanical Synthesis platform and in its ability
Biotechnology, Pharmaceuticals, Health
2025-09-10 7:00 AM EDT | BioHarvest Sciences Inc.
Hemostemix Announces Private Placement
Calgary, Alberta--(Newsfile Corp. - September 9, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, announces a non broke
Biotechnology, Pharmaceuticals, Health
2025-09-09 8:47 AM EDT | Hemostemix Inc.
Envoy Medical Secures Four New Global Patents, Expanding Its Leadership Position in Fully Implantable Hearing Technology
White Bear Lake, Minnesota--(Newsfile Corp. - September 9, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of four new global patents. These patents expand the company's global intellectual property portfolio and mark another strategic step in delivering next-generation cochlear implant solutions that offer patients discreet, 24/7 hearing experience wit
Biotechnology, Healthcare and Hospitals
2025-09-09 8:00 AM EDT | Envoy Medical, Inc.
CellCentric Announces Completion of Enrollment for Dose Optimization Cohorts in Phase 2 Study for Multiple Myeloma
United Kingdom and Boston, Massachusetts--(Newsfile Corp. - September 9, 2025) - CellCentric, a clinical-stage biotechnology company developing inobrodib, a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma (MM), today announced completion of patient enrollment in the randomized dose optimization portion of its Phase 1
2025-09-09 7:00 AM EDT | CellCentric, Inc
Hemostemix Launches Enhanced HubSpot-Powered Websites to Support Global Marketing & Sales of ACP-01 for No-Option Patients
Calgary, Alberta--(Newsfile Corp. - September 9, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, announces the launch
Biotechnology, Pharmaceuticals, Health
2025-09-09 6:13 AM EDT | Hemostemix Inc.
Telo Geonomics Announces Engagement of Investor Relations Service Provider
Vancouver, British Columbia--(Newsfile Corp. - September 8, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") announces that it has engaged Hayden IR, LLC. ("Hayden"), a U.S.-based investor relations consulting firm, to enhance the Company's investor relations strategy by increasing awareness of the Company, its technologies, and its business prospects. On August 20, 2025, the Company entered into an investor relations services
2025-09-08 4:20 PM EDT | Telo Genomics Corp.
Optimind Pharma Announces Definitive Agreement for Proposed Change of Business with InterviewDesk
Toronto, Ontario--(Newsfile Corp. - September 8, 2025) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") is pleased to announce that it has entered into a binding definitive share exchange agreement dated September 5, 2025 (the "SEA") with IDesk Technologies Private Limited ("InterviewDesk"), a private company incorporated under laws of India, and its principal shareholders in respect of an arm's length transaction (the "Transaction") whi
Biotechnology, Cannabis, Health, Psychedelics
2025-09-08 3:18 PM EDT | Optimind Pharma Corp.
Envoy Medical to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025
White Bear Lake, Minnesota--(Newsfile Corp. - September 8, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced today announced that Brent Lucas, Envoy Medical's Chief Executive Officer, will present virtually at the H.C. Wainwright 27th Annual Global Investment Conference, which is being held September 8-10, 2025 in New York City. Mr. Lucas' presentation is now av
Biotechnology, Healthcare and Hospitals
2025-09-08 8:00 AM EDT | Envoy Medical, Inc.
Optimi Announces Public Filing of Registration Statement for Proposed U.S. Initial Public Offering
Vancouver, British Columbia--(Newsfile Corp. - September 8, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company") a Canadian drug manufacturer of MDMA and naturally-derived psilocybin announces that it has publicly filed a registration statement with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed initial public offering of its common shares in the United States. The number of common share
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-09-08 7:00 AM EDT | Optimi Health Corp.
PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - September 5, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news release dated August 5, 2025, it has closed an initial tranche (the "Initial Tranche") of its previously announced $1,000,000 non-brokered private placement (the "Offering"), which Initial Tranche consisted of the issuance of 16,162,500 unit
Biotechnology, Pharmaceuticals, Health
2025-09-05 4:58 PM EDT | PreveCeutical Medical Inc.